Skip to main content
Premium Trial:

Request an Annual Quote

Robert Hershberg

NanoString Technologies announced that Robert Hershberg has joined its board of directors as of March 2, bringing the total number of members to six.

Hershberg in July 2014 became VP of immuno-oncology at Celgene Corporation. He leads Celgene's early R&D efforts in that space and is in charge of the new Celgene Immuno-Oncology Center of Excellence in Seattle, Washington. Hershberg also founded and is CEO of VentiRx Pharmaceuticals and is an independent member of the board of directors for Adaptive Biotechnologies Corporation. 

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.